Overview

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
Phase:
PHASE3
Details
Lead Sponsor:
AstraZeneca
Treatments:
tezepelumab